Use of new oral anticoagulants in antiphospholipid syndrome

Current Rheumatology Reports

Volumn 15, Issue 6, 2013, Pages

  Arachchillage, Deepa Jayakody ^a   Cohen, Hannah ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Antiphospholipid syndrome; Bleeding; Breastfeeding; Drug interactions; New oral anticoagulants; Perioperative management; Pregnancy; Warfarin

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMIODARONE; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; CARBAMAZEPINE; CLARITHROMYCIN; CYTOCHROME P450 3A4 INHIBITOR; DABIGATRAN ETEXILATE; EDOXABAN; ENZYME INHIBITOR; FLUCONAZOLE; GLYCOPROTEIN P INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; LIXIANA; LOW MOLECULAR WEIGHT HEPARIN; PHENOBARBITAL; PHENYTOIN; PHOSPHOLIPID ANTIBODY; PROTON PUMP INHIBITOR; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANEMIA; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BONE MALFORMATION; BRAIN HEMORRHAGE; BREAST FEEDING; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED EMESIS; CONSERVATIVE TREATMENT; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG WITHDRAWAL; DYSPEPSIA; ELECTIVE SURGERY; EMBOLISM; EMBRYOTOXICITY; EMERGENCY SURGERY; EPIDURAL ANESTHESIA; EPISTAXIS; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; FAINTNESS; FECES; FETUS MALFORMATION; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENITOURINARY BLEEDING; GINGIVA BLEEDING; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; LIMB PAIN; LIVER DYSFUNCTION; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; MUCOSAL BLEEDING; NAUSEA; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PATIENT COUNSELING; PERIOPERATIVE PERIOD; PLACENTA DISORDER; PREDICTION; PREGNANCY; PROPHYLAXIS; PROTHROMBIN TIME; PRURITUS; REPRODUCTIVE TOXICITY; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SPINAL ANESTHESIA; SYSTEMIC EMBOLISM; TACHYCARDIA; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; URINARY EXCRETION; VENOUS THROMBOEMBOLISM; ADULT; ANALOGS AND DERIVATIVES; ANIMAL; CONTRAINDICATIONS; ENVIRONMENTAL EXPOSURE; FEMALE; NEWBORN; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL (TOPIC); PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, ORAL; ADULT; ANIMALS; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BENZIMIDAZOLES; BETA-ALANINE; BREAST FEEDING; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG MONITORING; FEMALE; HUMANS; INFANT, NEWBORN; MATERNAL EXPOSURE; MORPHOLINES; PREGNANCY; PYRAZOLES; PYRIDINES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES; THIOPHENES;

EID: 84891701713     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0331-5     Document Type: Article

References (64)

1. Miyakis S, Lockshin MD, Atsumi D, et al. International consensus statement on an update of the preliminary classification criteria for antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
2. Austin S, Cohen H. Antiphospholipid syndrome. Medicine. 2009;34:472-5. (Pubitemid 44882715)
3. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-94S.
4. Keeling D et al. British Committee for Standards in Haematology (BCSH) - Guidelines for General Haematology, Haemostasis and Thrombosis. Guidelines on oral anticoagulation with warfarin fourth edition. Br J Haematol. 2011;154:311-24.
5. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta M. Antiphospholipid syndrome. Lancet. 2010;376:1498-509.
6. Pradaxa 150 mg hard capsules: summary of product characteristics (SPC), EU. Boehringer Ingelheim International GmBH, 21/09/2012. Available from: www.emc.medicines.org.uk.
7. Xarelto 10 mg film-coated tablets. Summary of product characteristics (SPC), EU. Bayer HealthCare AG. Date of first authorisation/renewal of authorisation: 30/09/08. Date of revision 12/2011. Available from: www.emc.medicines.org.uk.
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
9. Patel MR, Mahaffey KW, Gar J, Pan G, Singe DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (and supplementary appendix). N Engl J Med. 2011;365:883-91.
10. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency 26/07/2012 Pradaxa -EMEA/H/C/000829 -II/0032.
11. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. 09/12/2011 Xarelto -EMEA/H/C/000944 -X/0010.
12. NICE technology appraisal guidance 249. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation.March 2012. www.nice.org.uk/TA249.
13. NICE technology appraisal guidance 256. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation.May 2012. www.nice.org.uk/TA 256.
14. Erikkson BI, Dahl OE, Rosencher N, RE-MODEL Study Group, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the Re-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-85. (Pubitemid 47617868)
15. Eriksson BI, Dahl OE, Rosencher N, RE-NOVATE Study group, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949-56. (Pubitemid 47393577)
16. Eriksson BI, Borris LC, Dahl OE, RECORD 2 Investigators, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl JMed. 2008;358:2765-75. (Pubitemid 351930851)
17. Kakkar AK, Brenner B, Dahl OE, RECORD 2 Investigators, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind randomised controlled trial. Lancet. 2008;372:31-9.
18. Lassen MR, Ageno W, Borris LC, RECORD 3 Investigators, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-86. (Pubitemid 351930852)
19. Turpie AG, Lassen MR, Davidson BL, RECORD 4 Investigators, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement (RECORD 4): a randomised trial. Lancet. 2009;373:1673-80.
20. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism. Annu Rev Med. 2011;62:41-57.
21. Frost C, Yu Z, Nepal S, Mosqueda-Garcia R, Shenker A. Apixaban, an oral direct, factor Xa inhibitor: multiple ascending-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost. 2007;5 Suppl 2:P-M-664.
22. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial:design and rationale. Am Heart J. 2010;159:331-9.
23. Ogata K et al. Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers. J Clin Pharmacol. 2010;50:743-53.
24. Patel M, for the ROCKET AF Study Investigators. Rivaroxaban-Once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340-7.
25. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation- Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160:635-41.
26. Approval Drugs by FDA available from. http://www.fda.gov/Drugs/ InformationOnDrugs/ApprovedDrugs.
27. •• EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism (and supplementary appendix). N Engl J Med. 2010;363:2499-510. This is a key trial on the use of rivaroxaban for the treatment of venous thromboembolism.
28. Reference ID: 3212129. Available from: www.accessdata.fda.gov/scripts/ cder/drugsatfda.
29. NICE technology appraisal guidance 261. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. July 2012. www.nice.org.uk/TA 261.
30. Guidance in development. Dabigatran etexilate for the treatment of acute venous thromboembolic events (ID108). www.nice.org.uk.
31. Xarelto 20 mg film-coated tablets. Summary of product characteristics (SPC), EU. Bayer HealthCare AG. Last updated on the eMC: 04/12/2012.Available from: www.emc.medicines.org.uk.
32. •• EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97. This is a key trial on the efficacy of rivaroxaban for the treatment of symptomatic pulmonary embolism.
33. Guidance in development. Pulmonary embolism (acute treatment, VTE prevention) - rivaroxaban [ID569]. www.nice.org.uk.
34. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;36(6):594-604.
35. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807-15.
36. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement (ADVANCE-3). N Engl J Med. 2010;363(26):2487-98.
37. NICE technology appraisal guidance 245.Venous thromboembolism - apixaban (hip and knee surgery). January 2012. www.nice.org.uk/TA 245.
38. Eliquis 2.5 mg film-coated tablets film-coated tablets Summary of Product Characteristics (SPC) last updated on the eMC: 03/12/2012. Available from: www.emc.medicines.org.uk.
39. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92.
40. Guidance in development. Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban [ID500]. www.nice.org.uk.
41. Schulman S, Kearon C, Kakkar, for the Re-COVER Study Group, et al. Dabigatran versus warfarin for the treatment of acute venous thromboembolism. N Engl Med. 2009;361:2341-52.
42. Agnelli G, Buller HR, Cohen A et al. Apixaban for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2012 Dec 8.
43. Development status of rivaroxaban, apixaban edoxaban and dabigatran (www.clinicaltrials.gov).
44. RAPS trail details available at. http://isrctn.org/ISRCTN68222801.
45. Harder S. Renal profiles of anticoagulants. J Clin Pharmacol. 2012;52(7):964-75.
46. Baglin T et al. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidence from British Committee for Standards in Haematology. Br J Haematol. 2012. doi: 10.1111/bjh.12052 [Epub ahead of print].
47. • Samama MM, Guinet C. Laboratory assessments of new anticoagulants. Clin Chem Lab Med. 2011;49:761-72. This paper provides useful information on laboratory aspects of NOAC.
48. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Hemost. 2010;103(4):815-25.
49. Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol. 2010;85:185-7.
50. • van Os GM, de Laat B, Kamphuisen PW, et al. Detection of lupus anticoagulants in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost. 2011;9:1657-9. This small in vitro study investigates the detection of lupus anticoagulants in the presence of rivaroxaban.
51. Merriman E, Kaplan Z, Butler J, et al. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost. 2012;105:385-6.
52. Fareed J, Thethi I, Hoppensteadt D. Old Versus New Oral Anticoagulants: Focus on Pharmacology. Annu Rev Pharmacol Toxicol. 2012;52:79-99.
53. Pengo V, Crippa L, Falanga A, et al. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost. 2012;10(10):1979-87.
54. Buller HR. Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism, the Einstein-Extension Study. Late Breaking Abstracts LBA-2. 51st ASH Annual Meeting and Exposition 2009.
55. Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus. 2010;19:486-91.
56. Frank Peacock W, Gearhart MM, Mills RM. Emergency Management of Bleeding Associated with Old and New Oral Anticoagulants. Clin Cardiol. 2012. doi: 10.1002/clc.22037 [Epub ahead of print].
57. •• Eerenberg ES, Kamphuisen PW, Sijpken MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-9. This study demonstrates that prothrombin complex concentrate corrects the coagulopathy caused by rivaroxaban but not that of dabigatran.
58. Makris M, Joost J, Van Veen JJ, Campbell R, Tait CR, et al. Guideline on the management of bleeding in patients on antithrombotic agents. BJ Haem. 2012;160:35-46.
59. Turpie AGG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban -an oral, direct factor Xa inhibitor. Thromb Haemost. 2012;108:876-86.
60. Spyropoulos ACD, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120(15):2954-62.
61. • Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016-23. This article provides authoritative advice on the clinical use of NOAC.
62. Douketis JD et al. Perioperative management of antithrombotic therapy: antithrombotic therapy band prevention of thrombosis 9th Edition: ACCP. Chest. 2012;141:e326Se350S.
63. Llau JV, Ferrandis R. New anticoagulants and regional anesthesia. Curr Opin Anaesthesiol. 2009;22:661-6.
64. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010;27:999-1015.